Next Phase Newsletter

Founded by entrepreneurs with deep sector experience, a venture capital firm headquartered in Western Europe, focused on novel therapeutics. The firm is an early-stage investor, investing from seed through late stage pre-clinical. The firm will typically stay with the asset until after clinical proof-of-concept, at which point they will exit. The firm is currently investing from a Europe-focused fund, and plans to invest in more USA-based companies with their next fund. The firm makes initial investments of $3M – $5M in equity and occasionally convertible loans. The firm can make follow-on investments, up to a total of $15-20M per investment.

The firm is solely focused on therapeutics. The firm is indication- and modality- agnostic. The firm’s larger focus is on stage of development and that there is a large unmet need with high commercial value.

The firm will both lead and co-invest. They do not have strict team requirements, though prefer for teams with previous experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A multinational conglomerate with multiple business areas including healthcare has been an active investor and strategic partner in areas that complement their core businesses, such as regenerative medicine, cell therapy, drug discovery enabling technologies, etc., through means of strategic investment, in-licensing, M&A, research collaborations.

The firm manages a life sciences strategic investment fund that seeks to invest in life science companies developing cutting edge technologies with high growth potential across the globe. Initial investment sizes will start with in the few hundred thousand range, and the firm focuses on Series A and B investments with potential for follow-ons.

The firm’s strategic investment fund is actively seeking new opportunities in life sciences. While mainly opportunistic towards specific sectors, technologies, and indications, the firm prioritizes investment opportunities that complement their core business areas including diagnostics, therapeutics, R&D enabling technologies and platforms. The firm seeks early-stage opportunities, and are open to those that are in pre-clinical stage / in development.

The firm will generally participate as a co-investor. The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in the US is actively investing from their second fund. The firm is actively investing in the intersection of science, technology, and neurology, and has invested in over 30 companies to date. The firm invests primarily in Seed to Series A rounds. While the firm has mostly invested in USA-based companies, the firm is open to opportunities beyond.

Within life sciences, the firm is interested in drug development and drug development-enabling tools and technologies, medical devices with a software component, and wearables. Relating to therapeutics, the firm is particularly interested in psychedelics and plant-based therapies. The firm is most interested in technologies that target mental & behavioral health and CNS/neurodegenerative disease. The firm is open to early-stage, pre-clinical companies.

The firm has no specific company or management team requirements, and is open to acting as either lead or co-investor, seeking board representation when leading rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A global venture capital fund headquartered in Asia has a strong focus in the microbiome and adjacent fields. Atypical for a VC, the firm has multiple mechanisms to support early-stage innovators and entrepreneurs. In addition to equity investments, they have a sponsored research function that provides grants for academics or startups conducting fundamental research, which may lead to future pipelines or newco. They are also involved in developing a deep phenotyping platform that follows changes in the microbiome of healthy participants for an extended period of time. 

For capital investments, the firm is stage and country agnostic but tends to prefer earlier stages (Seed and Series A). Their interest within the microbiome field is diverse and not limited to therapeutics.  As scientists, entrepreneurs, and operators themselves, the firm fundamentally values the underlying science, team, as well as potential synergy with their mission and existing portfolio companies. Moreover, for startups looking to enter Asian markets, the firm provides additional value through their extensive networks and track record of launching businesses in these geographies. 
 
The firm is looking to partner with groups addressing complex challenges with the potential to impact society globally, with a preference for first-in-class or best-in-class innovations. While not exclusive, their current areas of high interest are: 1) skin microbiome/gut-skin axis, 2) women’s and infant microbiome, 3) gut-brain axis, 4) phage therapy, gene editing, and virome. That said, the firm is open to any promising opportunities, even if they are not directly focused on the microbiome, provided they include amazing teams with a global vision to positively impact society. 
 
The firm is looking for companies and technologies that can move its mission forward and have multiple options for funding, including equity investing and non-dilutive funding. They usually prefer syndicate investments with a smaller cheque size as an initial investment but may lead with substantial follow-on investments once the relationship is established.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based the UK invests in early-stage health-tech companies from Seed to Series A/A+ with check sizes ranging from GBP £500k-£3M. The firm is open to global companies but has a bias to UK, Europe and Israel.  
 
The firm invests in digital diagnostics, digital therapeutics and medical devices. The firm is generally indication-agnostic but has a bias to oncology, cardiovascular, mental health, diabetes, women’s health and health AI. 
 
The firm can be a lead or co-investor and typically takes board or observer seats. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A VC firm with offices in US and Asia invests primarily in therapeutics, with a secondary focus in molecular diagnostics and digital health. For those fields, the firm is interested in first-in-class technology approaches and will invest in early companies with great science, from seed to series A. With their expansion to the US, the firm is now open to investing globally. The firm has generally led investments, but is willing to be part of a syndicate as well. The firm’s investments range based on the stage of the company, but will generally be no more than $5M for seed stage and no more than $10M for series A rounds. 
 
Within therapeutics, the firm is open to both subsector and indication as long as the science is breakthrough. The firm is willing to invest earlier in platform technology companies, and will consider such technologies as early as POC stage. For companies with single assets in development, the firm prefers to see at least small animal data. For molecular diagnostics and digital health companies, the firm is opportunistic as well. 
 
Because the firm invests early in companies with breakthrough science, they are willing to help their portfolio companies develop their strategies and operations. With its broad and trustful network with pharma companies, the firm helps portfolio companies’ boost their businesses development activities. The firm will take a board seat after investment if needed to help the company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A privately held investment firm operating within a family office structure focuses on early-stage investments across multiple sectors, including life sciences and healthcare. The firm’s sweet spot is pre-seed investments but is open to opportunities from Seed to Series A. The firm’s typical check size is $200k USD per round, with a range of $100k USD to $300k USD, and follow-on investments are possible. While the firm typically does not lead funding rounds, they can serve as technical leads and provide memos for co-investors. The firm is open to opportunities globally. 
 
The firm is primarily interested in therapeutics platforms, enabling technologies and tools for scientists, while also open to considering the more asset-focused companies. The firm is indication agnostic, but tends to avoid investing in companies developing products too similar to those in their current portfolio. In terms of development stages, the firm is open to pre-clinical stage assets with some proof of concepts, which doesn’t necessarily need to be in-vivo. While they are open to engaging with companies in the “idea phase”, it might be too early for investment. The firm prefers to invest early and generally considers assets already in the IND phase or companies generating revenue too late. 
 
The firm does not have specific requirements for the management team. The firm prefers technical teams with complementary skill sets, and are coachable and driven. The firm is an active investor and will consider board or observer seats on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.